Eosinophilia Is Associated with Improved COVID-19 Outcomes in Inhaled Corticosteroid-Treated Patients.
Eosinophilia Is Associated with Improved COVID-19 Outcomes in Inhaled Corticosteroid-Treated Patients.
复制标题
DOI：
10.1016/j.jaip.2021.12.034
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Ortega VE
中科院分区：
文献类型：
--
作者：
Zein JG;Strauss R;Attaway AH;Hu B;Milinovich A;Jawhari N;Chamat SS;Ortega VE
除了它们的促炎作用外，嗜酸性粒细胞还具有抗病毒特性。同样，吸入皮质类固醇（ICS）在体外抑制冠状病毒复制，并与2019冠状病毒病（COVID-19）的改善结果相关。然而，两者之间的相互作用及其对COVID-19的影响需要进一步评估。确定预先存在的血液绝对嗜酸性粒细胞计数、ICS和covid -19相关结果之间的关系。我们分析了克利夫兰诊所COVID-19研究登记处（2020年4月1日至2021年3月31日）的数据。在82096名检测呈阳性的个体中，46397人在严重急性呼吸综合征冠状病毒2检测日期之前获得了血液差异细胞计数。我们的终点包括住院需求、入住重症监护病房（ICU）和住院死亡率。在倾向加权和调整后估计嗜酸性粒细胞对结果的影响。在最终分析的46,397例患者中，19,506例既往存在嗜酸性粒细胞增多症（>0.15 × 103细胞/μL）， 5,011例接受了ICS， 9,096例（19.6%）住院，2,129例（4.6%）需要ICU住院，1,402例在指数住院期间死亡（3.0%）。校正分析表明，在接受ics治疗的患者中，嗜酸性粒细胞增多与住院（比值比[OR][95%可信区间（CI）]: 0.86[0.79-0.93]）、ICU入院（OR [95% CI]: 0.79[0.69-0.90]）和死亡率（OR [95% CI]: 0.80[0.68-0.95]）的几率较低。在未接受ICS治疗的患者中，绝对嗜酸性粒细胞计数与住院、ICU入院和死亡的估计概率呈非线性（u型）相关，而在接受ICS治疗的患者中为负相关。嗜酸性粒细胞增多与COVID-19预后改善之间的关联取决于ICS。需要未来的随机对照试验来确定ICS的作用及其与嗜酸性粒细胞增多症在COVID-19治疗中的相互作用。
In addition to their proinflammatory effect, eosinophils have antiviral properties. Similarly, inhaled corticosteroids (ICS) were found to suppress coronavirus replication in vitro and were associated with improved outcomes in coronavirus disease 2019 (COVID-19). However, the interplay between the two and its effect on COVID-19 needs further evaluation. To determine the associations among preexisting blood absolute eosinophil counts, ICS, and COVID-19–related outcomes. We analyzed data from the Cleveland Clinic COVID-19 Research Registry (April 1, 2020 to March 31, 2021). Of the 82,096 individuals who tested positive, 46,397 had blood differential cell counts obtained before severe acute respiratory syndrome coronavirus 2 testing dates. Our end points included the need for hospitalization, admission to the intensive care unit (ICU), and in-hospital mortality. The effect of eosinophilia on outcomes was estimated after propensity weighting and adjustment. Of the 46,397 patients included in the final analyses, 19,506 had preexisting eosinophilia (>0.15 × 103 cells/μL), 5,011 received ICS, 9,096 (19.6%) were hospitalized, 2,129 required ICU admission (4.6%) and 1,402 died during index hospitalization (3.0%). Adjusted analysis associated eosinophilia with lower odds for hospitalization (odds ratio [OR] [95% confidence interval (CI)]: 0.86 [0.79-0.93]), ICU admission (OR [95% CI]: 0.79 [0.69-0.90]), and mortality (OR [95% CI]: 0.80 [0.68-0.95]) among ICS-treated patients but not untreated ones. The correlation between absolute eosinophil count and the estimated probability of hospitalization, ICU admission, and death was nonlinear (U-shaped) among patients not treated with ICS, and negative in treated patients. The association between eosinophilia and improved COVID-19 outcomes depends on ICS. Future randomized controlled trials are needed to determine the role of ICS and its interaction with eosinophilia in COVID-19 therapy.
登录
查看更多内容
影响因子：
12.3
作者：
Aschenbrenner AC;Mouktaroudi M;Krämer B;Oestreich M;Antonakos N;Nuesch-Germano M;Gkizeli K;Bonaguro L;Reusch N;Baßler K;Saridaki M;Knoll R;Pecht T;Kapellos TS;Doulou S;Kröger C;Herbert M;Holsten L;Horne A;Gemünd ID;Rovina N;Agrawal S;Dahm K;van Uelft M;Drews A;Lenkeit L;Bruse N;Gerretsen J;Gierlich J;Becker M;Händler K;Kraut M;Theis H;Mengiste S;De Domenico E;Schulte-Schrepping J;Seep L;Raabe J;Hoffmeister C;ToVinh M;Keitel V;Rieke G;Talevi V;Skowasch D;Aziz NA;Pickkers P;van de Veerdonk FL;Netea MG;Schultze JL;Kox M;Breteler MMB;Nattermann J;Koutsoukou A;Giamarellos-Bourboulis EJ;Ulas T;German COVID-19 Omics Initiative (DeCOI)
通讯作者：
German COVID-19 Omics Initiative (DeCOI)
DOI：
10.1183/13993003.03142-2020
发表时间：
2021-03
期刊：
The European respiratory journal
影响因子：
--
作者：
Izquierdo JL;Almonacid C;González Y;Del Rio-Bermudez C;Ancochea J;Cárdenas R;Lumbreras S;Soriano JB
通讯作者：
Soriano JB
DOI：
10.1126/science.abc6261
发表时间：
2020-09-04
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Arunachalam PS;Wimmers F;Mok CKP;Perera RAPM;Scott M;Hagan T;Sigal N;Feng Y;Bristow L;Tak-Yin Tsang O;Wagh D;Coller J;Pellegrini KL;Kazmin D;Alaaeddine G;Leung WS;Chan JMC;Chik TSH;Choi CYC;Huerta C;Paine McCullough M;Lv H;Anderson E;Edupuganti S;Upadhyay AA;Bosinger SE;Maecker HT;Khatri P;Rouphael N;Peiris M;Pulendran B
通讯作者：
Pulendran B
影响因子：
8.8
作者：
Dennis JM;McGovern AP;Vollmer SJ;Mateen BA
通讯作者：
Mateen BA
影响因子：
7.3
作者：
Diao, Bo;Wang, Chenhui;Chen, Yongwen
通讯作者：
Chen, Yongwen